Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Latanoprost Ophthalmic Solution (02489570). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
LATANOPROST
All products: Limited Use (codes 171, 172, 387)
Other products in the same Health Canada class (S01E, S01EE) — coverage varies; not interchangeable
- Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit
- Travoprost (Izba): limited Use 171, 172, 387
- Acetazolamide (Acetazolamide): general benefit, Not a benefit
- Betaxolol (Betoptic S): general benefit
- Levobunolol (Betagan): general benefit
- Methazolamide (Neptazane): general benefit, Not a benefit
9 more in the class list below
Apo-Latanoprost · DIN 02296527 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Latanoprost · DIN 02296527
Manufacturer: Apotex Inc.; listing date 2011-12-15
Health Canada: Marketed since 2018-07-03 · brand APO-LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Apotex inc · schedule Prescription
Apo-Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78185 · Verify on the e-Formulary ↗ (DIN 02296527)
Source record
DIN 02296527: Apo-Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id APX
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02296527
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78185
Interchangeable products
Co Latanoprost · DIN 02254786 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: active shortage (reported 2026-02-10, last updated 2026-02-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02296527
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gd-Latanoprost · DIN 02373041 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gd-Latanoprost · DIN 02373041
Manufacturer: Upjohn Canada ULC; listing date 2011-12-15
Health Canada: Marketed since 2023-11-16 · brand MYLAN-LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Mylan pharmaceuticals ulc · schedule Prescription
Gd-Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85817 · Verify on the e-Formulary ↗ (DIN 02373041)
Source record
DIN 02373041: Gd-Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id UJC
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02373041
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85817
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Co Latanoprost · DIN 02254786 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: resolved shortage (ended 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02373041
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Latanoprost · DIN 02453355 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Latanoprost · DIN 02453355
Manufacturer: Jamp Pharma Corporation; listing date 2020-03-31
Health Canada: Marketed since 2023-10-13 · brand JAMP LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Jamp pharma corporation · schedule Prescription
Jamp Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93988 · Verify on the e-Formulary ↗ (DIN 02453355)
Source record
DIN 02453355: Jamp Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id JPC
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453355
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93988
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Co Latanoprost · DIN 02254786 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: resolved shortage (ended 2026-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453355
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Latanoprost · DIN 02513285 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Latanoprost · DIN 02513285
Manufacturer: Mantra Pharma Inc.; listing date 2022-03-31
Health Canada: Marketed since 2021-11-10 · brand M-LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Mantra pharma inc · schedule Prescription
M-Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100250 · Verify on the e-Formulary ↗ (DIN 02513285)
Source record
DIN 02513285: M-Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id MAT
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02513285
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100250
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Co Latanoprost · DIN 02254786 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: resolved shortage (ended 2026-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02513285
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Med-Latanoprost · DIN 02426935 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Med-Latanoprost · DIN 02426935
Manufacturer: Generic Medical Partners Inc.; listing date 2015-03-31
Health Canada: Marketed since 2015-01-09 · brand MED-LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Generic medical partners inc · schedule Prescription
Med-Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91148 · Verify on the e-Formulary ↗ (DIN 02426935)
Source record
DIN 02426935: Med-Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id GMP
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426935
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91148
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Co Latanoprost · DIN 02254786 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: resolved shortage (ended 2019-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02426935
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Riva-Latanoprost · DIN 02341085 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Riva-Latanoprost · DIN 02341085
Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31
Health Canada: Marketed since 2015-05-28 · brand RIVA-LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Laboratoire riva inc. · schedule Prescription
Riva-Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82663 · Verify on the e-Formulary ↗ (DIN 02341085)
Source record
DIN 02341085: Riva-Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id RIA
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02341085
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82663
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Co Latanoprost · DIN 02254786 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: resolved shortage (ended 2022-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02341085
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Latanoprost · DIN 02367335 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Latanoprost · DIN 02367335
Manufacturer: Sandoz Canada Inc.; listing date 2012-11-27
Health Canada: Marketed since 2011-12-06 · brand SANDOZ LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Sandoz canada incorporated · schedule Prescription
Sandoz Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85213 · Verify on the e-Formulary ↗ (DIN 02367335)
Source record
DIN 02367335: Sandoz Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id SDZ
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367335
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85213
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Co Latanoprost · DIN 02254786 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: resolved shortage (ended 2026-06-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367335
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Xalatan · DIN 02231493 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Xalatan (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Xalatan · DIN 02231493
Manufacturer: Upjohn Canada ULC; listing date 2000-01-17
Health Canada: Marketed since 2023-07-31 · brand XALATAN · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Bgp pharma ulc · schedule Prescription
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50823 · Verify on the e-Formulary ↗ (DIN 02231493)
Source record
DIN 02231493: Xalatan
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id UJC
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $36.2736; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231493
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50823
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Co Latanoprost · DIN 02254786 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Shortage status: resolved shortage (ended 2023-03-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231493
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Co Latanoprost · DIN 02254786 · 0.005% · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2024-03-20 — choose a marketed DIN from the same-category list.Discontinued 2024-03-20 · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2024-03-20 — choose a marketed DIN from the same-category list.
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2024-03-20 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Co Latanoprost · DIN 02254786
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19
Health Canada: Cancelled post market since 2024-03-20 · brand TEVA-LATANOPROST · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Teva canada limited · schedule Prescription
Co Latanoprost: Formulary list price $9.5830/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.5830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73994 · Verify on the e-Formulary ↗ (DIN 02254786)
Source record
DIN 02254786: Co Latanoprost
Raw flags: sec12=Y, sec3=Y
Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id COB
Source form: Oph Sol-2.5mL Pk; strength: 0.005%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.5830; ministry $9.5830
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02254786
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73994
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830
Gd-Latanoprost · DIN 02373041 · $9.5830
Jamp Latanoprost · DIN 02453355 · $9.5830
M-Latanoprost · DIN 02513285 · $9.5830
Med-Latanoprost · DIN 02426935 · $9.5830
Riva-Latanoprost · DIN 02341085 · $9.5830
Sandoz Latanoprost · DIN 02367335 · $9.5830
Xalatan · DIN 02231493 · $9.5830
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02254786
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-03-20 — choose a marketed DIN from the same-category list.
LATANOPROST & TIMOLOL MALEATE
All products: Limited Use (codes 310, 393)
Other products in the same Health Canada class (S01E, S01EE) — coverage varies; not interchangeable
- Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit
- Travoprost (Izba): limited Use 171, 172, 387
- Acetazolamide (Acetazolamide): general benefit, Not a benefit
- Betaxolol (Betoptic S): general benefit
- Levobunolol (Betagan): general benefit
- Methazolamide (Neptazane): general benefit, Not a benefit
9 more in the class list below
Act Latanoprost/Timolol · DIN 02436256 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Act Latanoprost/Timolol · DIN 02436256
Manufacturer: Actavis Pharma Company; listing date 2015-11-26
Health Canada: Marketed since 2025-01-10 · brand TEVA-LATANOPROST-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Teva canada limited · schedule Prescription
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92058 · Verify on the e-Formulary ↗ (DIN 02436256)
Source record
DIN 02436256: Act Latanoprost/Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id ACV
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0700; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436256
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92058
Interchangeable products
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02436256
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gd-Latanoprost/Timolol · DIN 02373068 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gd-Latanoprost/Timolol · DIN 02373068
Manufacturer: Upjohn Canada ULC; listing date 2013-08-29
Health Canada: Marketed since 2023-11-16 · brand MYLAN-LATANOPROST/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, LATANOPROST 50 MCG/ML · company Mylan pharmaceuticals ulc · schedule Prescription
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85818 · Verify on the e-Formulary ↗ (DIN 02373068)
Source record
DIN 02373068: Gd-Latanoprost/Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id UJC
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0700; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02373068
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85818
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: active shortage (reported 2026-07-28, estimated to end 2026-09-22, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02373068
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Latanoprost/Timolol · DIN 02453770 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Latanoprost/Timolol · DIN 02453770
Manufacturer: Jamp Pharma Corporation; listing date 2020-03-31
Health Canada: Marketed since 2020-02-07 · brand JAMP-LATANOPROST/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, LATANOPROST 50 MCG/ML · company Jamp pharma corporation · schedule Prescription
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94031 · Verify on the e-Formulary ↗ (DIN 02453770)
Source record
DIN 02453770: Jamp-Latanoprost/Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id JPC
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0700; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453770
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94031
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-08-07, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453770
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Latanoprost / Timolol · DIN 02553848 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Latanoprost / Timolol · DIN 02553848
Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31
Health Canada: Marketed since 2026-06-03 · brand LATANOPROST / TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Jamp pharma corporation · schedule Prescription
Latanoprost / Timolol: Formulary list price $11.0670/unit (unit not stated in source; not the patient's cost)
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104274 · Verify on the e-Formulary ↗ (DIN 02553848)
Source record
DIN 02553848: Latanoprost / Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id JPC
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0670; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553848
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104274
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553848
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Latanoprost-Timolol · DIN 02514516 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Latanoprost-Timolol · DIN 02514516
Manufacturer: Mantra Pharma Inc.; listing date 2022-03-31
Health Canada: Marketed since 2021-11-10 · brand M-LATANOPROST-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Mantra pharma inc · schedule Prescription
M-Latanoprost-Timolol: Formulary list price $11.0670/unit (unit not stated in source; not the patient's cost)
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100369 · Verify on the e-Formulary ↗ (DIN 02514516)
Source record
DIN 02514516: M-Latanoprost-Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id MAT
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0670; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02514516
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100369
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: resolved shortage (ended 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02514516
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Med-Latanoprost-Timolol · DIN 02454505 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Med-Latanoprost-Timolol · DIN 02454505
Manufacturer: Generic Medical Partners Inc.; listing date 2020-03-31
Health Canada: Marketed since 2019-08-22 · brand MED-LATANOPROST-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Generic medical partners inc · schedule Prescription
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94108 · Verify on the e-Formulary ↗ (DIN 02454505)
Source record
DIN 02454505: Med-Latanoprost-Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id GMP
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0700; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454505
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94108
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454505
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Xalacom · DIN 02246619 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)Savings card: RxHelp ONE lists Xalacom (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Xalacom · DIN 02246619
Manufacturer: Upjohn Canada ULC; listing date 2004-11-04
Health Canada: Marketed since 2023-07-24 · brand XALACOM · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, LATANOPROST 50 MCG/ML · company Bgp pharma ulc · schedule Prescription
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70807 · Verify on the e-Formulary ↗ (DIN 02246619)
Source record
DIN 02246619: Xalacom
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id UJC
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $41.0578; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246619
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70807
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Shortage status: resolved shortage (ended 2022-12-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246619
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Latanoprost-Timop · DIN 02414155 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Latanoprost-Timop · DIN 02414155
Manufacturer: Apotex Inc.; listing date 2014-10-29
Health Canada: Dormant since 2017-08-04 · brand APO-LATANOPROST-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Apotex inc · schedule Prescription
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89884 · Verify on the e-Formulary ↗ (DIN 02414155)
Source record
DIN 02414155: Apo-Latanoprost-Timop
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id APX
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0700; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02414155
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89884
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Sandoz Latanoprost/Timolol · DIN 02394685 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414155
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2017-08-04 — choose a marketed DIN from the same-category list.
Sandoz Latanoprost/Timolol · DIN 02394685 · 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Limited Use — Reason for Use code 310, 393 required; Health Canada lists this DIN as Cancelled post market since 2019-04-26 — choose a marketed DIN from the same-category list.Discontinued 2019-04-26 · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required; Health Canada lists this DIN as Cancelled post market since 2019-04-26 — choose a marketed DIN from the same-category list.
Write on scriptLU code 310, 393 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2019-04-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Latanoprost/Timolol · DIN 02394685
Manufacturer: Sandoz Canada Inc.; listing date 2013-04-30
Health Canada: Cancelled post market since 2019-04-26 · brand SANDOZ LATANOPROST/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Sandoz canada incorporated · schedule Prescription
Ministry pays: $11.0670 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87982 · Verify on the e-Formulary ↗ (DIN 02394685)
Source record
DIN 02394685: Sandoz Latanoprost/Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600108; group id 630; item number 1599; lccId 00157; manufacturer id SDZ
Source form: Oph Sol-2.5mL Pk; strength: 50mcg/mL & 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $11.0700; ministry $11.0670
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394685
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87982
Interchangeable products
Act Latanoprost/Timolol · DIN 02436256 · $11.0670
Apo-Latanoprost-Timop · DIN 02414155 · $11.0670
Gd-Latanoprost/Timolol · DIN 02373068 · $11.0670
Jamp-Latanoprost/Timolol · DIN 02453770 · $11.0670
Latanoprost / Timolol · DIN 02553848 · $11.0670
M-Latanoprost-Timolol · DIN 02514516 · $11.0670
Med-Latanoprost-Timolol · DIN 02454505 · $11.0670
Xalacom · DIN 02246619 · $11.0670
Shortage status: resolved shortage (ended 2019-04-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394685
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-04-26 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered
Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL
Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE
52:36 Other Eye, Ear, Nose and Throat Agents
· 8 products · Listed, not a benefit (1),
Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk
· 4 products ·
Limited Use, codes 171, 172, 387 · strengths: 0.003%, 0.004% · Oph Sol (with Preservative), Oph Sol-5mL Pk
· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab
· 1 products · General benefit · strengths: 0.25% · Oph Susp
· 1 products · General benefit · strengths: 0.5% · Oph Sol
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab
· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol
· 7 products ·
Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol
· 3 products ·
Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk
· 1 products ·
Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp
· 1 products ·
Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk
· 1 products ·
Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36
and 18 more
Availability
Apo-Latanoprost · DIN 02296527
Shortage status: active shortage (reported 2026-02-10, last updated 2026-02-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02296527
Check this DIN againCo Latanoprost · DIN 02254786
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02254786
Check this DIN againAct Latanoprost/Timolol · DIN 02436256
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02436256
Check this DIN againGd-Latanoprost/Timolol · DIN 02373068
Shortage status: active shortage (reported 2026-07-28, estimated to end 2026-09-22, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02373068
Check this DIN againJamp-Latanoprost/Timolol · DIN 02453770
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-08-07, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453770
Check this DIN againApo-Latanoprost-Timop · DIN 02414155
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414155
Check this DIN again